A Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 (GENERIUM JSC, Russia) in Subjects With Solid Advanced Malignancies
Latest Information Update: 12 Mar 2024
At a glance
- Drugs GNR-051 (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors GENERIUM Pharmaceuticals
- 05 Mar 2024 Planned End Date changed from 1 Jun 2024 to 1 Jan 2025.
- 22 Feb 2023 Planned End Date changed from 15 Jun 2024 to 1 Jun 2024.
- 22 Feb 2023 Status changed from recruiting to active, no longer recruiting.